X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	60.49	99.22	121.72	81.79	78.71	126.18
Short-Term Investments	20.38	15	0	0	0	0
Cash & Cash Equivalents	80.87	114.22	121.72	81.79	78.71	126.18
Cash Growth	-13.42%	-6.16%	48.82%	3.91%	-37.62%	1451.32%
Receivables	0.7	0.56	1.15	0.75	0.92	2
Other Current Assets	5.76	7.3	5.81	5.34	3.68	1.1
Total Current Assets	87.33	122.08	128.68	87.88	83.31	129.28
Property, Plant & Equipment	6.01	6.4	8.33	10.22	9.2	2.36
Goodwill and Intangibles	17.35	17.35	17.35	17.35	27.11	27.11
Other Long-Term Assets	1.49	1.44	1.23	1.72	3.26	1.95
Total Long-Term Assets	24.85	25.18	26.91	29.3	39.56	31.42
Total Assets	112.18	147.26	155.59	117.18	122.87	160.7
Accounts Payable	8.94	8.95	7.78	4.28	3.14	2.09
Current Debt	1.13	1.1	2.51	1.87	0.79	0.9
Other Current Liabilities	13.47	12.82	12.03	7.87	8.02	6.46
Total Current Liabilities	23.54	22.86	22.32	14.02	11.95	9.45
Long-Term Debt	57.14	57.18	35.91	37.92	37.66	22.02
Other Long-Term Liabilities	30.46	16.12	23.3	0.83	0.46	0.02
Total Long-Term Liabilities	87.61	73.3	59.21	38.74	38.12	22.03
Total Liabilities	111.15	96.16	81.54	52.76	50.07	31.48
Total Debt	58.28	58.28	38.42	39.79	38.45	22.91
Debt Growth	57.79%	51.69%	-3.43%	3.48%	67.80%	133.05%
Retained Earnings	-529.67	-477.91	-376.74	-282.87	-194.18	-132.04
Comprehensive Income	-0.16	-0.12	-0.12	-0.12	-0.12	-0.12
Shareholders' Equity	1.04	51.1	74.05	64.41	72.8	129.22
Net Cash / Debt	22.59	55.94	83.3	42	40.26	103.27
Net Cash / Debt Growth	-59.99%	-32.85%	98.32%	4.33%	-61.02%	-
Net Cash Per Share	0.11	0.31	1.31	1.63	2.01	8.96
Working Capital	63.79	99.21	106.35	73.86	71.36	119.83
Book Value Per Share	0.01	0.29	1.17	2.50	3.63	11.21

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).